A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

581

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis

Interventions

DRUG: 0.15% azelastine hydrochloride
DRUG: 0.1% azelastine hydrochloride
DRUG: Placebo

Sponsor

Meda Pharmaceuticals